Dr. John Minna, Core Co-Director and SPORE principal investigator and Dr. Jack Roth, Core Director and Co-Principal Investigator of the SPORE will provide the administrative leadership for Core A. They will facilitate the interactions of the project and core leaders and direct their SPORE activities to accomplish the following aims: 1. To direct the overall scientific quality of the SPORE and ensure communication, cooperation, and integration between The University of Texas Southwestern (UTSW) and The University of Texas MD Anderson Cancer Center (UTMDACC). 2. To monitor the overall compliance of the SPORE in conjunction with all general Governmental and specific NCI regulations and requirements. 3. Communicate and confer with the NCI Project Officer and other staff, and ensure all necessary reporting requirements. 4. Coordinate data quality control and quality assurance issues in conjunction with the Internal Review and Monitoring Committees of UTSW and MDACC and the Biostatistics and Bioinformatics (Core C). 5. Oversee expenditures and maintain budget information. 6. Organize all necessary meetings, including the Executive Committee, External and Internal Advisory Committees, monthly scientific videoconference meetings, lectures, symposia, and attendance at the Lung Cancer SPORE meetings. 7. Oversee the Developmental Research and Career Development Programs including obtaining mentors, biostatistical, and bioinformatics support and assist in selection of projects for funding. Specifically establish and monitor policies for recruitment of women and minorities to this program. 8. Coordinate and maintain Institutional commitment to the SPORE at UTSW and MDACC. 9. Encourage and facilitate inter SPORE communication, collaborations, cooperation, data and resource sharing. 10. Coordinate and facilitate SPORE interactions with the PHARMA and Biotech industry 11. Coordinate and facilitate Patient Advocate involvement in the SPORE.
The SPORE Administrative Core provides scientific and administrative oversight for all of the SPORE Projects and Cores and the Developmental and Career Development Program. It also provides the main interface with the NCI, other Lung Cancer SPOREs, and other collaborating institutions.
|Ma, Junsheng; Hobbs, Brian P; Stingo, Francesco C (2018) Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. Stat Methods Med Res 27:2093-2113|
|Yi, Faliu; Yang, Lin; Wang, Shidan et al. (2018) Microvessel prediction in H&E Stained Pathology Images using fully convolutional neural networks. BMC Bioinformatics 19:64|
|Song, Kai; Bi, Jia-Hao; Qiu, Zhe-Wei et al. (2018) A quantitative method for assessing smoke associated molecular damage in lung cancers. Transl Lung Cancer Res 7:439-449|
|Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221|
|He, Min; Liu, Shanshan; Gallolu Kankanamalage, Sachith et al. (2018) The Epithelial Sodium Channel (?ENaC) Is a Downstream Therapeutic Target of ASCL1 in Pulmonary Neuroendocrine Tumors. Transl Oncol 11:292-299|
|Parra, Edwin R; Villalobos, Pamela; Behrens, Carmen et al. (2018) Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer 6:48|
|Guo, Hou-Fu; Tsai, Chi-Lin; Terajima, Masahiko et al. (2018) Pro-metastatic collagen lysyl hydroxylase dimer assemblies stabilized by Fe2+-binding. Nat Commun 9:512|
|Meraz, Ismail M; Majidi, Mourad; Cao, Xiaobo et al. (2018) TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras-Mutant Mouse Lung Cancer Models. Cancer Immunol Res 6:163-177|
|Zhang, Liren; Lin, Jing; Ye, Yuanqing et al. (2018) Serum MicroRNA-150 Predicts Prognosis for Early-Stage Non-Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1. Clin Pharmacol Ther 103:1061-1073|
|Bayo, Juan; Tran, Tram Anh; Wang, Lei et al. (2018) Jumonji Inhibitors Overcome Radioresistance in Cancer through Changes in H3K4 Methylation at Double-Strand Breaks. Cell Rep 25:1040-1050.e5|
Showing the most recent 10 out of 1059 publications